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Introduction: The purpose of this study is to develop a prediction model utilizing tumor hemoglobin parameters
measured by ultrasound-guided near-infrared optical tomography (US-NIR) in conjunction with standard pathologic
tumor characteristics to predict pathologic response before neoadjuvant chemotherapy (NAC) is given.
Methods: Thirty-four patients’ data were retrospectively analyzed using a multiple logistic regression model to
predict response. These patients were split into 30 groups of training (24 tumors) and testing (12 tumors) for cross
validation. Tumor vascularity was assessed using US-NIR measurements of total hemoglobin (tHb), oxygenated
(oxyHb) and deoxygenated hemoglobin (deoxyHb) concentrations acquired before treatment. Tumor pathologic
variables of tumor type, Nottingham score, mitotic index, the estrogen and progesterone receptors and human
epidermal growth factor receptor 2 acquired before NAC in biopsy specimens were also used in the prediction
model. The patients’ pathologic response was graded based on the Miller-Payne system. The overall performance of
the prediction models was evaluated using receiver operating characteristic (ROC) curves. The quantitative measures
were sensitivity, specificity, positive and negative predictive values (PPV and NPV) and the area under the ROC
curve (AUC).
Results: Utilizing tumor pathologic variables alone, average sensitivity of 56.8%, average specificity of 88.9%,
average PPV of 84.8%, average NPV of 70.9% and average AUC of 84.0% were obtained from the testing data.
Among the hemoglobin predictors with and without tumor pathological variables, the best predictor was tHb
combined with tumor pathological variables, followed by oxyHb with pathological variables. When tHb was
included with tumor pathological variables as an additional predictor, the corresponding measures improved to
79%, 94%, 90%, 86% and 92.4%, respectively. When oxyHb was included with tumor variables as an additional
predictor, these measures improved to 77%, 85%, 83%, 83% and 90.6%, respectively. The addition of tHb or oxyHb
significantly improved the prediction sensitivity, NPV and AUC compared with using tumor pathological variables
alone.
Conclusions: These initial findings indicate that combining widely used tumor pathologic variables with hemoglobin
parameters determined by US-NIR may provide a powerful tool for predicting patient pathologic response to NAC
before the start of treatment.
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Preoperative or neoadjuvant chemotherapy (NAC) is in-
creasingly used in the management of locally advanced
breast cancers, as well as in patients with lower tumor
stages, to increase the rate of breast-conserving therapy
and to reduce the extent of surgery [1-3]. Complete
eradication of invasive tumor cells in the primary tumor
bed following neoadjuvant therapy is strongly correlated
with improved disease-free survival and overall survival
[4]. Furthermore, clinical trials in the NAC setting are
increasingly being conducted to study new agents and
novel therapeutic strategies in breast cancer using patho-
logical complete response (pCR), a surrogate marker for
survival, as the primary endpoint [5]. Several pathologic
variables, such as invasive ductal carcinoma, high tumor
grade and high proliferative activity, are associated with
a better response to NAC [6-8]. Classifying breast can-
cers into molecular subtypes has significantly improved
the understanding of preoperative chemotherapy out-
comes and has helped guide the selection of treatment
[9-11]. Recent studies have established that breast can-
cers that are basal-like or “triple-negative” (estrogen re-
ceptor–negative (ER−), progesterone receptor–negative
(PR−) and human epidermal growth factor receptor
2–negative (HER2−)) respond best to cytotoxic therapies
[11,12] and that HER2-positive (HER2+) tumors respond
best to trastuzumab-based regimens [13]. In particular,
in HER2+ breast cancer, the NAC approach has yielded
great successes. The dual HER2 blockade with trastu-
zumab and pertuzumab recently has shown the highest
pCR rates ever reported [3]. The NAC approach has
yielded much higher rates of pCR in patients with triple-
negative breast cancers than for patients with other
breast tumor types. However, more than half of triple-
negative breast cancer patients do not achieve a pCR
and have a very poor prognosis [14]. Current studies are
focused on identifying molecular subtypes of triple-
negative tumors and their clinical relevancy by deter-
mining pCR rates after NAC [15,16]. Recent studies have
also shown that luminal A subtype tumors (ER + and
HER2− and low tumor grade or low-proliferative phe-
notype) exhibit lower sensitivity to standard cytotoxic-
based regimens [17].
Nomograms, which integrate clinical and pathological
variables including tumor receptors and number of che-
motherapy courses using multiple logistic regression
model, have been developed to predict complete pa-
thological response on the basis of preoperative treat-
ment [18-20]. However, reliable individualized prediction
of a pathological complete response after preoperative
chemotherapy based on conventional pathologic tumor
characteristics determined before the start of treatment
is difficult, and the response to chemotherapy varies
among patients [21,22].In the past decade, optical tomography and optical spec-
troscopy using near-infrared (NIR) diffused light has de-
monstrated great potential in the assessment of the tumor
vasculature response to NAC [23-30]. The NIR technique
utilizes intrinsic hemoglobin contrast, which is directly re-
lated to tumor angiogenesis, a key process required for
tumor growth and metastasis. In our recent paper pub-
lished in Radiology [30], we demonstrated, for the first
time to our knowledge, that the baseline pretreatment
total hemoglobin (tHb), oxygenated hemoglobin (oxyHb)
and deoxygenated hemoglobin (deoxyHb) levels were
significantly higher in the tumors with near-complete or
complete pathologic response than they were in the tu-
mors with modest or no response to NAC. These mea-
surements are directly related to tumor blood volume,
perfusion, metabolism and tumor vasculature characteris-
tics. Our new finding suggests that hypervascular tumors
respond to NAC significantly better than hypovascular
tumors do. In a recent study in which diffuse optical
spectroscopy was used, Ueda et al. reported that the pre-
treatment tumor oxygen saturation = oxyHb/tHb × 100
correlated with pathological complete response for pa-
tients undergoing NAC [31]. To the best of our know-
ledge, our study and theirs are the only published ones in
which prediction of NAC on the basis of pretreatment
hemoglobin measurements has been described. Water has
previously been reported to be sensitive to cell death, and
its reduction may reflect a progressive loss of tumor cellu-
larity and edema for at least 1 week [23,32] or for 4 weeks
[27] after initiation of NAC. Lipid and scatter measuring
tumor tissue structure have not been reported as early pre-
dictors after the initiation of NAC, because more time may
be needed before tumor size changes are detectable [23].
In this article, we introduce a novel prediction model
using a multiple logistic regression model by incorpo-
rating widely used tumor pathologic variables of tumor
type, grade and mitotic index, tumor receptors (triple-
negative, HER2+ versus HER2−, ER− versus ER2+) and
pretreatment functional parameters of tHb, oxyHb and
deoxyHb. We assess the contributions of the hemoglobin
functional parameters on improving the prediction sensi-
tivity, specificity, positive predictive value (PPV), negative
predictive value (NPV) and area under the receiving ope-
rating characteristic (ROC) curve (AUC), and we compare
these measures with and without those obtained from
conventional tumor pathologic characteristics.
Methods
Patients
Patients were recruited from Hartford Hospital and the
University of Connecticut Health Center (UCHC) from
December 2007 to May 2011. The study protocol was
approved by the institutional review board of the Human
Subjects Protection Office of UCHC and Hartford Hospital
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and Accountability Act). Written informed consent was
obtained from all patients. Details of the patient study were
reported previously [30]. Briefly, 32 patients who were
treated with neoadjuvant chemotherapy were assessed pre-
treatment, at the end of each treatment cycle and prior to
surgery using ultrasound-guided near-infrared optical to-
mography (US-NIR). Two more patients who completed
the same study procedures and excluded in the previous
report [30] were included in this study because the present
study is focused on assessing pretreatment prediction. One
patient had an inflammatory breast cancer with very low
measurable vascular content throughout the treatment,
and the other was an elderly patient treated differently
from the rest. Patients’ tumor types, grades (Nottingham
score), mitotic index scores and receptor status of ER, PR
and HER2 obtained at core biopsy are summarized in
Table 1 with the two patients discussed above listed at the
bottom of the table.
The 34 total patients (mean age, 48 years; range, 32 to
82 years) were initially split into a training group of 23 pa-
tients with a total of 24 tumors enrolled into this study
during the first 3 years of the recruitment period and a
testing group of 11 patients with a total of 12 tumors. Of
these latter 11 patients, 9 patients were enrolled in the last
7 months of the recruitment period and two more were
enrolled as discussed in the paragraph above. Thus, two-
thirds of the patients are being used for training and one-
third for testing. Owing to the small patient sample,
especially the limited numbers of triple-negative tumors
(n = 6), HER2+ tumors (n = 6) and invasive lobular carcin-
omas (ILCs) (n = 5), we performed cross-validation by ran-
domly splitting the six triple-negative tumors, six HER2+
tumors and five ILCs between training and testing data sets
while keeping approximately two-thirds of the samples of
each subcategory in the training data sets. So, 24 pairs of
training and testing data sets were generated. Additionally,
the rest of the patients were randomly split into training
and testing data sets to generate six more pairs of training
and testing data sets while keeping approximately a similar
percentage (30% to 50%) of patients who achieved a
complete or nearly complete response to NAC in each pair
of training and testing data sets. Thus, a total of 30 pairs of
training and testing data sets were generated to train, valid-
ate and compare the prediction models.
Among the 34 patients, 28 HER2- patients were treated
with paclitaxel-based regimens (dose-dense doxorubicin/
cyclophosphamide/paclitaxel, docetaxel/cyclophosphamide,
doxorubicin/cyclophosphamide/docetaxel, and bevaci-
zumab), and 6 HER2+ patients were treated with a
trastuzumab-based regimen (docetaxel/carboplatin with
trastuzumab). The final pathologic response was assessed
using the Miller-Payne grading system [33], in which
pathologic response is divided into five grades based oncomparison of tumor cellularity between pre-neoadjuvant
core biopsy and definitive surgical specimen. The Miller-
Payne grading system is as follows:
 Grade 1: no change or some minor alteration in
individual malignant cells, but no reduction in
overall cellularity
 Grade 2: a minor loss of tumor cells, but overall
high cellularity; up to 30% reduction of cellularity
 Grade 3: between an estimated 30% and 90%
reduction in tumor cellularity
 Grade 4: a marked disappearance of more than 90%
of tumor cells such that only small clusters or
widely dispersed individual cells remain (almost
pCR)
 Grade 5: no invasive malignant cells identifiable in
sections from the site of the tumor (pCR)
For this study, the Miller-Payne grades 4 and 5 patients
were grouped as responders and grades 1 to 3 were groups
as nonresponders. There were a total of 21 grades 1 to 3
tumors and 15 grade 4 or 5 tumors with a response rate
of 42%.
Hemoglobin parameters
The imager consisted of a handheld probe with nine
source fibers and ten detection light guides deployed
around a commercial US probe. The US images were
used to localize the tumor and were acquired simul-
taneously with the NIR data. For each patient, tumor ab-
sorption maps obtained at four optical wavelengths of
740, 780, 808 and 830 nm were reconstructed. From the
absorption maps, the tHb, deoxyHb and oxyHb maps
were calculated and the maximum tHb, deoxyHb and
oxyHB concentrations were measured. Several quality
NIR images at the tumor location were used to compute
the average maximum tHb, deoxyHb and oxyHB values,
which were used to characterize each tumor as reported
elsewhere [30]. From phantom studies, we found that
the reconstructed maximum value closely represented
the true target value.
Statistical analysis and prediction model
Spearman’s rank correlation coefficient or Spearman’s ρ,
which is more appropriate for assessing the relationship
for both continuous and discrete variables, was computed
between each tumor’s Miller-Payne grade and the pre-
treatment maximum tHb, oxyHb and deoxyHb concentra-
tions; tumor types; Nottingham scores; mitotic index; and
tumor receptor status obtained at the core biopsy. Ad-
ditionally, the Spearman’s ρ between pretreatment para-
meters was computed. Ductal carcinomas were coded as
1, mixed ductal and lobular carcinomas were coded as 1
and lobular carcinomas were coded as 0. Triple-negative,
Table 2 Statistical analysis of Miller-Payne grades compared with pretreatment variablesa
Maximum tHb Maximum oxyHb Maximum deoxyHb Tumor type NS MC/10 hpf Triple-negative HER2 ER
Spearman’s ρ 0.520 0.455 0.395 0.408 0.545 0.538 0.261 0.305 0.375
P-value 0.001 0.005 0.017 0.013 0.001 0.001 0.124 0.070 0.024
adeoxyHb, Deoxygenated hemoglobin; ER, Estrogen receptor; HER2, Human epidermal growth factor receptor 2; hpf, High-power fields; MC, Mitotic count; NS,
Nottingham score; oxyHb, Oxygenated hemoglobin; tHb, Total hemoglobin.
Table 1 Patient demographicsa
Age, yr Tumor type (IDC, 1)
(IDC/ILC, 1) (ILC, 0 )
Nottingham




(+, 1) (−, 0)
HER2 (+, 1)
(−, 0)
ER (+, 0) (−, 1) Miller-Payne
grade
32 1 9 20 0 0 0 2
51 1 8 8 0 0 0 2
42 1 8 8 1 0 1 5
64 1 9 34 1 0 1 5
48 1 4 0 1 0 1 3
34 1 6 2 0 0 0 1
39 0 7 1 0 0 0 2
48 1 5 6 0 0 0 1
39 1 9 14 1 0 1 1
42 0 3 0 0 0 0 1
35 1 9 39 0 0 0 4
40 1 4 2 0 0 0 2
47 1 9 15 0 0 0 5
53 0 6 0 or 1 0 0 0 2
32 1 9 16 0 1 1 4
64 1 6 4 0 1 1 4
40 1 9 30 0 1 0 3
38 1 7 9 0 1 0 4
64 1 8 44 0 0 0 2
48 0 6 1 0 0 0 2
69 1 7 16 0 0 0 3
82 1 6 0 0 0 0 1
47b 1 8 10 0 0 0 5
38 1 9 20 1 0 1 5
49 1 6 8 0 0 0 3
63b 1 8 10 0 0 0 3
37 1 7 8 0 0 0 4
55 1 7 10 0 1 0 5
44 1 6 5 0 0 0 3
53 1 9 58 1 0 1 5
54 1 9 26 0 0 1 5
42 0 6 5 0 0 0 2
77 1 9 16 0 1 0 5
35 1 6 4 0 0 0 3
aER, Estrogen receptor; HER2, Human epidermal growth factor receptor 2; hpf, High-power fields; IDC, Invasive ductal carcinoma; IDC/ILC, Invasive mammary
carcinoma with mixed ductal and lobular features; ILC, Invasive lobular carcinoma. bTwo distinct tumors in the same breast with the same characteristics.
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Figure 1 Box-and-whisker plot of baseline total hemoglobin, oxygenated hemoglobin and deoxygenated hemoglobin of two responder
groups. deoxyHb, Deoxygenated hemoglobin; MP, Miller-Payne grade; oxyHb, Oxygenated hemoglobin; tHb, Total hemoglobin.
Zhu et al. Breast Cancer Research 2014, 16:456 Page 5 of 14
http://breast-cancer-research.com/content/16/6/456HER2 and ER tumor status was coded as 1 for triple-
negative and 0 for otherwise, 1 for HER2+ and 0 for
HER2−, and 0 for ER+ and 1 for ER−. Spearman’s cor-
relation calculations were performed using Minitab 15
software (Minitab, State College, PA, USA), and the re-
sults are given in Table 2.
Logistic regression is a statistical modeling approach
that can be used to describe the relationship of several
predictor variables, X1, X2, … Xk, to a dichotomous re-
sponse variable Y, where Y is coded as 1 (responder) or
0 (nonresponder) for its two possible categories [34].
The model can be written in a form that describes the
probability of occurrence of one of the two possible out-
comes of Y as follows:
prðY ¼ 1 j X1; X2; … XkÞ
¼ 1
1 þ exp − β0 þ Σkn ¼ 1 βnXn
 
The estimated outputs (probability) for each set of
predictor variables range from 0 to 1. The model be-
longs to the class of generalized linear models based on
the exponential distribution family. Given the data for Y,
X1, X2, … Xk, the unknown parameters βn, n = 0, 1, …, k
can be estimated using the maximum likelihood method.
In this article, we estimate and validate the 13 logisticTable 3 Statistical analysis of pretreatment hemoglobin param
tHb oxyHb deoxyHb Tumor type NS
tHb 0.841 0.637 0.166 0.43
P < 0.001 P < 0.001 P = 0.333 P =
oxyHb 0.302 0.066 0.23
P = 0.074 P = 0.703 P =
deoxyHb 0.050 0.35
P = 0.771 P =
adeoxyHb, Deoxygenated hemoglobin; ER, Estrogen receptor; HER2, Human epiderm
Nottingham score; oxyHb, Oxygenated hemoglobin; tHb, Total hemoglobin.models and their prediction power using combinations
of 12 sets of predictor variables of tumor characteristics
(tumor type, Nottingham score and mitotic counts),
tumor pathological variables (tumor characteristics and
receptor status of triple-negative, HER2 and ER), five
pairs of hemoglobin predictor variables of tHb, oxyHb
and deoxyHb only, tHb and oxyHb (tHboxyHb), and
tHb and deoxyHb (tHbdeoxyHb), without tumor patho-
logical variables and with these variables. The MATLAB
(version 2008a; MathWorks, Natick, MA, USA) logistic
regression function glmfit was used to compute the coef-
ficients βn, where n = 0, 1, …, k, and glmval was used to
predict the response from these coefficients for the train-
ing set. The same coefficients obtained from the training
set were used to predict the response for the testing set.
We also assess the overall performance of the pre-
diction models through the ROC curves and the AUC
for all training and testing sets. For this purpose, the
estimated outputs ranging from 0 to 1 were inputted to
the R console (version R 2.15.2; The R Project for Statis-
tical Computing, Vienna, Austria), and the R open source
software package pROC [35] was used in the R console to
compute the ROC curve and AUC for each model using
combined predictor variables. The 95% confidence inter-
val (CI) of each AUC was obtained using 10,000 stratified
bootstrap replicates, and the average CIs obtained frometers with tumor pathological variablesa
MC/10 hpf Triple-negative HER2 ER
0 0.206 0.108 0.144 0.312
0.009 P = 0.229 P = 0.532 P = 0.404 P = 0.064
4 0.005 0.115 0.108 0.330
0.170 P = 0.979 P = 0.505 P = 0.532 P = 0.049
6 0.292 0.093 0.086 0.275
0.033 P = 0.084 P = 0.589 P = 0.618 P = 0.105
al growth factor receptor 2; hpf, High-power field; MC, Mitotic count; NS,
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old of 0.5 was used to separate responders (>0.5) from
nonresponders (≤0.5) for each prediction model output
and prediction sensitivity, specificity, PPV and NPV were
calculated accordingly. In Minitab 15, a two-sample, two-
sided t-test was used to calculate the statistical significance
of differences in the sensitivity, specificity, PPV, NPV and
AUC of different models. P <0.05 was considered statisti-
cally significant.
Results and discussion
A box-and-whisker plot of pretreatment maximum tHb,
oxyHb and deoxyHb values obtained from responder andFigure 2 Box-and-whisker plots of area under the receiver operating
of predictor variables. (a) Training data. (b) Testing data. Char, Predictor
count; Char+Rec, Predictor variables of tumor characteristics and receptor s
(HER2), estrogen receptor (ER); tHb, oxyHb, deoxyHb: Predictor variables of pre
(oxyHb) and deoxygenated hemoglobin (deoxyHb), respectively; tHboxyHb, t
deoxyHb, respectively; Char+Rec+corresponding hemoglobin variables: Comb
corresponding hemoglobin predictors. ROC, Receiver operating characteristicnonresponder groups is shown in Figure 1. The corre-
sponding mean values (SD) of pretreatment maximum
tHb, oxyHb and deoxyHb values were 107.9 ± 33.2 μmol/L,
70.3 ± 23.1 μmol/L and 46.5 ± 17.6 μmol/L, respectively,
for responders. The corresponding values were 72.8 ±
22.5 μmol/L, 45.5 ± 17.6 μmol/L and 34.1 ± 11.5 μmol/L
for nonresponders (P = 0.001, P = 0.001 and P = 0.017, re-
spectively) (Figure 1). The Spearman’s correlation coeffi-
cients of these parameters with Miller-Payne grades are
summarized in Table 2. The maximum tHb, deoxyHb and
oxyHb values correlate well with the final pathological re-
sponse. Correlation coefficients of the other pathological
predictor variables with Miller-Payne grades are alsocharacteristic curves obtained from prediction models of 12 sets
variables of tumor characteristics of type, Nottingham score, mitotic
tatus of triple-negative, human epidermal growth factor receptor 2
treatment maximum total hemoglobin (tHb), oxygenated hemoglobin
HbdeoxyHb: Combined predictor variables of tHb and oxyHb, tHb and
ined predictor variables of tumor characteristics, receptor status and
.
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Nottingham score, mitotic count and ER status corre-
late well with the final pathological response, and the
triple-negative and HER2+ tumors also show reasonable
correlation with the final pathological response. Patient
age was not correlated with the Miller-Payne grade
(Spearman’s ρ = 0.127, P = 0.473) and was not used as a
predictor variable.
The Spearman’s correlation coefficients between pre-
treatment hemoglobin parameters and tumor pathological
variables are given in Table 3. It is interesting to note that
tHb and deoxyHb correlate well with tumor Nottingham
score (P = 0.009 and P = 0.033, respectively) and that tHb
and oxyHb show a moderate negative correlation with
tumor ER expression (P = 0.064 and P = 0.049, respec-
tively). Note that ER+was coded as 0, and ER−was coded
as 1. These results suggest that tumor hemoglobin levels
estimated using the US-NIR imager measure the aggres-
siveness of breast cancers.
AUC statistics obtained from two sets of predictor vari-
ables of tumor characteristics (tumor type, Nottingham
score and mitotic count), tumor pathological variables
(tumor characteristics and receptor status of triple-negative,
HER2, ER) are shown in the first two columns of Figure 2.
The horizontal axis indicates the predictor variables. On
average, the addition of the tumor receptor status improves
the AUC from 76.9% (95% CI, 59.5; 95.46) to 87.1% (95%
CI, 71.54; 98.63) in the training data (P <0.001) (Figure 2a)
and from 80.0% (95% CI, 51.11; 99.29) to 84.0% (95% CI,
57.16; 99.03) in the testing data (P = 0.087) (Figure 2b).
Additionally, five pairs of hemoglobin predictor variables of
tHb, oxyHb, deoxyHb, tHboxyHb and tHbdeoxyHb with-
out tumor pathological variables and with these variables














IDC/ILC, NS, MC TN, HER2, ER tHb
IDC/ILC, NS, MC TN, HER2, ER oxyHb
IDC/ILC, NS, MC TN, HER2, ER deoxyHb
IDC/ILC, NS, MC TN, HER2, ER tHb, oxyHb
IDC/ILC, NS, MC TN, HER2, ER tHb, deoxyHb
aCI, confidence interval; deoxyHb, Deoxygenated hemoglobin; ER, Estrogen recepto
carcinoma; IDC/ILC, Invasive mammary carcinoma with mixed ductal and lobular fe
score; oxyHb, Oxygenated hemoglobin; NPV, Negative predictive value; PPV, PositivAUCs of training and testing results, as well as average 95%
CIs of all 12 prediction models using a different set of pre-
dictor variables, are summarized in Tables 4 and 5. For
training data shown in (Figure 2a), the addition of the
tumor pathological variables to each set of hemoglobin pre-
dictors significantly improves the AUC and tightens up the
95% CI as compared with data obtained without the patho-
logical variables (P ≤ 0.001). The AUCs obtained from the
hemoglobin predictors with tumor pathological variables
are significantly higher than those of the pathological vari-
ables alone (P <0.001), except deoxyHb and deoxyHb with
the tumor pathological variables pair (P = 0.068), which ap-
proaches statistical significance. For the testing data shown
in Figure 2b, the combined predictor set of tHb with tumor
pathological variables and oxyHb with these variables out-
perform tHb and oxyHb alone (P = 0.030 and P = 0.004, re-
spectively) and pathological variables alone (P = 0.001 and
P = 0.007, respectively). On average, the AUCs of tHb and
oxyHb with tumor pathological variables are 92.4% (95%
CI, 79.42; 99.80) and 90.6% (95% CI, 74.36; 99.35), respec-
tively, as compared with 87.3% (95% CI, 62.13; 99.82) and
84.0% (95% CI, 56.01; 100), respectively, obtained without
the pathological variables. Note that the 95% CI is much
tighter with the addition of pathological variables. However,
the other three sets of hemoglobin predictors combined
with tumor pathological variables did not achieve statistical
significance as compared with the tumor pathological va-
riables alone. One reason is that tHb is correlated with
oxyHb and deoxyHb (see Table 3). However, oxyHb and
deoxyHb are independent variables. Because the signal-to-
noise ratio of estimated tHb and oxyHb is much higher
than that of deoxyHb, the tHb and oxyHb pair and tHb
and deoxyHb pair are more robust predictors than the





AUC (%) (95% CI)
76.2/74.3 65.7/83.1 76.9 (59.60; 95.46)
71.1/80.7 70.5/81.6 87.1 (71.54; 98.63)
58.1/84.5 69.9 /75.9 76.7 (53.01; 96.64)
52.9/86.1 71.5/73.8 76.8 (54.60; 94.34)
59.3/81.8 68.1/75.9 67.4 (40.97; 90.09)
60.3/87.9 77.1/77.5 78.6 (55.46; 97.08)
64.1/85.2 74.3/78.5 74.6 (55.58; 97.31)
80.5/87.6 80.8/87.5 92.9 (82.76; 99.70)
79.9 /91.4 85.2/87.9 96.1 (88.91; 100.0)
73.0/82.0 72.9/82.9 88.9 (74.94; 98.94)
92.5/95.2 92.5/95.2 98.2 (93.68; 100.0)
83.9/87.2 80.7/89.7 95.1 (86.94; 99.75)
r; HER2, Human epidermal growth factor receptor 2; IDC, Invasive ductal
atures; ILC, Invasive lobular carcinoma; MC, Mitotic count; NS, Nottingham
e predictive value; tHb, Total hemoglobin; TN, Triple-negative.











AUC (%) (95% CI)
IDC/ILC, NS, MC 51.8/68.1 57.9/63.3 80.0 (51.11; 99.29)
IDC/ILC, NS, MC TN, HER2, ER 56.8/88.9 84.8/70.9 84.0 (57.16; 99.03)
tHb 63.2/82.1 75.0/72.8 87.3 (62.13; 99.82)
oxyHb 60.8/81.9 73.6/71.4 84.0 (56.01; 100.0)
deoxyHb 52.2/89.6 80.4/69.1 72.2 (36.55; 97.67)
tHb, oxyHb 64.4/82.1 75.2/73.4 85.0 (57.61; 99.82)
tHb, deoxyHb 60.7/80.6 73.3/70.9 79.5 (56.32; 97.82)
IDC/ILC, NS, MC TN, HER2, ER tHb 78.7/93.6 89.5/85.9 92.4 (79.42; 99.80)
IDC/ILC, NS, MC TN, HER2, ER oxyHb 76.9/85.2 82.6/83.3 90.6 (74.36; 99.35)
IDC/ILC, NS, MC TN, HER2, ER deoxyHb 60.1/85.0 78.4/71.8 85.0 (58.78; 98.95)
IDC/ILC, NS, MC TN, HER2, ER tHb, oxyHb 73.2/84.9 81.8/81.7 88.6 (72.21; 97.51)
IDC/ILC, NS, MC TN, HER2, ER tHb, deoxyHb 71.5/84.3 79.5/79.1 85.0 (63.09; 99.53)
aCI, confidence interval; deoxyHb, Deoxygenated hemoglobin; ER, Estrogen receptor; HER2, Human epidermal growth factor receptor 2; IDC, Invasive ductal
carcinoma; IDC/ILC, Invasive mammary carcinoma with mixed ductal and lobular features; ILC, Invasive lobular carcinoma; MC, Mitotic count; NS, Nottingham
score; oxyHb, Oxygenated hemoglobin; NPV, Negative predictive value; PPV, Positive predictive value; tHb, Total hemoglobin; TN, Triple-negative.
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of the tHb and oxyHb pair and the tHb and deoxyHb pair
contain information about tumor oxygenated and deo-
xygenated blood distributions. The combined predictor
deoxyHb with tumor pathological variables performs bet-
ter than deoxyHb alone (P <0.001). The validation data
suggest that the combined predictor variables of tHb or
oxyHb with tumor pathological variables are strong pre-
dictors of a patient’s final pathological response and are
more informative than the other three sets of combined
predictors.
Statistics of prediction sensitivity, specificity, PPV and
NPV obtained from two sets of predictor variables of
tumor characteristics, tumor pathological variables and
five pairs of hemoglobin predictor variables without and
with tumor pathological variables are shown in Figure 3
(training) and Figure 4 (testing), respectively. For the
training data shown in Figure 3 and Table 4, three pairs of
hemoglobin predictors of tHb, oxyHb, tHboxyHb com-
bined with tumor pathological variables significantly im-
prove prediction sensitivity, specificity, PPV and NPV as
compared with corresponding hemoglobin predictors
alone (P ≤ 0.012) and tumor pathological variables alone
(P ≤ 0.006). deoxyHb combined with pathological variables
does not improve the performance of these measures
as compared with tumor pathological variables alone;
tHbdeoxyHb combined with pathological variables does
not improve specificity, but it does improve the other
three measures. For the testing data shown in Figure 4
and Table 5, all hemoglobin predictors, except deoxyHb,
combined with pathological variables significantly improve
the prediction sensitivity and NPV as compared with
tumor pathological variables alone (P ≤ 0.05). On average,
the sensitivity and NPV of tHb, oxyHb, tHboxyHb,tHbdeoxyHb are 78.7% (P <0.001), 76.9% (P <0.001), 73.2%
(P = 0.001), 71.5% (P = 0.001) and 93.6% (P <0.001), and
85.2% (P <0.001), 84.9% (P <0.001) and 84.3% (P = 0.002),
respectively, as compared with 56.8% and 70.9% obtained
from pathological variables alone. However, no statistically
significant improvement is achieved in specificity and PPV
as compared with prediction using tumor pathological
variables alone. In general, all hemoglobin predictors
combined with pathological variables perform better than
hemoglobin predictors alone, except deoxyHb. tHb com-
bined with the pathological variables is the best predictor,
with an average 79% sensitivity, 94% specificity, 90%
PPV and 86% NPV. The second best predictor is oxyHb
combined with pathological variables, with corresponding
measures of 77%, 85%, 83% and 83%, respectively.
Taken together, our findings based on AUC, sensitivity,
specificity, PPV and NPV support the hypothesis that tHb
and oxyHb combined with tumor pathological variables
are strong pretreatment predictors of patient final patho-
logical response. Figure 5 shows a typical example of ROC
curves obtained from tumor pathological variables only
(Figure 5a), tHb without pathological variables (Figure 5b)
and tHb with pathological variables (Figure 5c), oxyHb
without pathological variables (Figure 5d) and oxyHb with
pathological variables. The AUC values computed by
pROC are 82.9%, 80.0%, 90%, 84.3% and 90%, respectively.
The 95% CI value is also given in each figure.
Different breast cancers have different degrees of che-
motherapy sensitivity. Conventionally used tumor his-
topathological variables have been used to predict a
patient’s pathological response. Immunohistochemistry
results of ER, PR and HER2 status have been routinely
evaluated in assisting and guiding the treatment selec-
tion. High tumor grade, ER−, triple-negative and HER2+
Figure 3 Training data. Box-and-whisker plot of sensitivity (a), specificity (b), positive predictive value (c), and negative predictive value (d) obtained
from 12 prediction models with predictor variables given along the x-axis. The predictor variables are the same as those given in Figure 2.
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Figure 4 Testing data. Box-and-whisker plot of sensitivity (a), specificity (b), positive predictive value (c), and negative predictive value (d) obtained
from 12 prediction models with predictor variables given along the x-axis. The predictor variables are the same as those given in Figure 2.
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Figure 5 (See legend on next page.)
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(See figure on previous page.)
Figure 5 Typical example of receiver operating characteristic curves obtained with pathological variables. (a) Receiver operating
characteristic curve (ROC) obtained from tumor pathological variables only. (b) ROC obtained from tumor tHb only. (c) ROC obtained
from tHb with pathological variables. (d) ROC obtained from oxyHb only. (e) ROC obtained from oxyHb. The 95% confidence interval is
also given in each figure.
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chemotherapy than other breast cancers. However, these
models have always fallen short. Our data derived from
34 patients demonstrate that 67% of triple-negative tu-
mors were Miller-Payne grade 5 and 83.3% of the HER2
+ tumors were grade 4 or 5 (Table 6). On the basis of
NIR pretreatment tHb level, we could predict responders
with 80% accuracy for grades 4 and 5 tumors. It is
known that ER+ tumors do not respond well to standard
paclitaxel-based regimens. Our data show that 80.9% of
the ER+ tumors were Miller-Payne grades 1 to 3. On the
basis of NIR pretreatment tHb level, we could predict
nonresponders with 69% accuracy for grades 1 and 2
tumors and 87.5% accuracy for grade 3 tumors (Table 6).
This result is comparable to that based on receptor
markers.
Our current study shows that when the pretreatment
measurements of hemoglobin content are used together
with histopathologic parameters as predictors in a multi-
variable prediction model, a substantially improved esti-
mation of patient treatment outcome, especially prediction
sensitivity and NPV, is obtained.
Ueda et al., using a diffuse optical spectroscopy
technique, found that the pretreatment tumor oxygen
saturation correlates with pathological complete re-
sponse for patients undergoing NAC [31]. Our
hemoglobin parameters were estimated from max-
imum values of US-guided tomographic images with
spatial and depth distributions. In tomography, oxy-
gen saturation = oxyHb/tHb × 100% can be obtained
pixel by pixel using tHb as a denominator, and it is
not robust for pixels with small tHb values. There-
fore, we did not compute oxygen saturation directly;
however, we show in Figure 1 that pretreatment tHb,
oxyHb, deoxyHb predict responders from nonre-
sponders with statistical significance.Table 6 Distributions of tumor receptor status and tumor res
Miller-Payne grades 1 and 2 Miller-P
Triple-negative (n = 6) n = 1 (17%, 1/6) n = 1 (17
ER− HER2+ (n = 6) n = 1 (16
ER+ HER2− (n = 21) n = 12(57.1%, 12/21) n = 5(23.
ER− PR + HER2− (n = 1)
Pretreatment tHb > Th n = 4 (31%, 4/13) n = 1 (12
Pretreatment tHb < Thb n = 9 (69%, 9/13) n = 7 (87
aER, Estrogen receptor; HER2, Human epidermal growth factor receptor 2; tHb, Tota
to separate responders (> Th = 90 μmol/L) from nonresponders (< Th). This threshoER− cancers are typically high-grade and more aggres-
sive. Our study shows that tHb and oxyHb inversely cor-
relate with ER expression. A related study was reported by
Koukourakis et al., who found an inverse association of
microvascular density with ER expression [36]. In another
study [37], Fuckar et al. reported a negative correlation
between vascular endothelial growth factor expression
and ER status. These ER− negative tumors were cha-
racterized by higher proliferative activity. The precise
mechanisms for oncogenic and angiogenic activities in
ER− breast cancer are not fully understood [38].
This study has limitations. First, the patient sample is
small, in particular the ILC, HER2+ and triple-negative
tumor cases. A large sample size would make the logistic
regression results more reliable because of the increased
number of observations in each case and thus the in-
creased accuracy in estimation of regression parameters
and improved prediction. However, the predictive values
of ILC, HER2+ and triple-negative tumors for NAC are
well-documented in the literature, and the new know-
ledge reported in this study is the improved prediction
of NAC by addition of hemoglobin parameters. Overfit-
ting could occur when three hemoglobin predictors, as
well as pretreatment optical scatter data, in addition to
tumor pathological variables were used as predictor vari-
ables to fit a limited set of training data points. As a re-
sult, the model memorizes the training data and is less
robust to generalize to an independent testing set. Cur-
rently, a larger-scale patient study is being designed to
validate the initial results reported in this article. More
data could allow robust estimation and validation of
additional predictor variables, such as pretreatment op-
tical scatter data and new biomarkers. Once validated
with a larger patient pool, it may serve as a benchmark
for preoperative chemotherapy prediction and also for
integrating newly discovered molecular markers andponses based on Miller-Payne gradesa
ayne grade 3 Miller-Payne grade 4 Miller-Payne grade 5
%, 1/6) n = 4 (67%, 4/6)
.7%, 1/6) n = 3 (50%, 3/6) n = 2 (33.3%, 2/6)
8%, 5/21) n = 2 (9.5%, 2/21) n = 2 (9.5%, 2/21)
n = 1 (100%)
.5%, 1/8) n = 3 (60%, 3/5) n = 9 (90%, 9/10)
.5%, 7/8) n = 2 (40%, 2/5) n = 1 (10%, 1/10)
l hemoglobin. bPrediction based on pretreatment tHb. Th is the threshold used
ld Th was selected in a previously reported study [30].
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were treated with standard chemotherapy regimens, in-
cluding anthracyclines, taxanes and trastuzumab. The
applicability of the prediction model to novel targeted
agents remains to be tested in future clinical trials.
Conclusions
As demonstrated by ROC analysis on testing data, tumor
pathologic predictor variables achieved an average pre-
diction sensitivity of 56.8%, specificity of 88.9%, PPV of
84.8%, NPV of 70.9% and AUC of 84.0%. tHb combined
with the tumor pathological variables is the best predictor,
with corresponding measures of 79%, 94%, 90%, 86% and
92.4%. oxyHb combined with pathological variables is
the second best predictor, with corresponding measures of
77%, 85%, 83%, 83% and 90.6%. The addition of tHb or
oxyHb significantly improves the prediction sensitivity,
NPV and AUC as compared with using tumor patho-
logical variables alone. Our initial data indicate that
combining widely used breast tumor pathologic variables
with novel tumor functional parameters of hemoglobin
(assessed by using a US-NIR technique) as predictor vari-
ables may provide a powerful tool for predicting patient
pathological response before the initiation of neoadjuvant
chemotherapy.
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